Oliver Leatham is a global market access expert and head of Evidence and Access at Certara. His team includes evidence evaluation, HTA, pricing, health economic modeling, and payer engagement. Oliver spe­cialises in market access strategic planning and innovative contracting, with the ability to identify opportunities and negotiate the acceptance of accelerated product approvals. Previously, Oliver worked as the head of pricing and market access for PAREXEL and Head of Market Access for Astellas, combining client-side insights with broader consultancy experience. Oliver has extensive experience in product commercialization, service redesign, payer engagement, and payer marketing. He sat on the AWMSG Steering Committee (HTA body for Wales) and has won awards for partnering with the healthcare providers. His novel approaches to innovative contracting and service redesign, including integrated care pathways and virtual clinics, have been showcased and replicated across a number of health economies in Europe.

Tim Lenehan has over 11 years of experience working in internationally fo­cussed market access roles, at the global and country level, and across mul­tiple therapeutic areas. He currently works for Biogen in Boston, where he is responsible for setting up and leading a market access innovation team. Prior to Biogen, Tim led global market access for Merck Serono’s fertility franchise, and before that he spent seven years with UCB in various roles including ini­tiating a global pricing role in their Brussels headquarters and setting up the Market Access function in their Russian affiliate in Moscow. In his free time, Tim enjoys spending time outdoors with his wife and two daughters and their Australian Shepherd, Akela.

Jörg Mahlich is a health economist for Janssen, Pharmaceutical Companies of Johnson and Johnson. Prior to his current position, he was an economist for the Austrian Eco­nomic Chamber. He has also been a lecturer at the University of Vienna and Fachhoch­schule Wien. He received his diploma in economics from Christian-Albrechts-Universitat zu Kiel and a Ph.D in economics in 2000 at the University of Vienna.

After studying statistics at the University of Dortmund (Germany) in 1988, Friedhelm Leverkus worked at the Social Research Centre in Dortmund. In 1991, he started his career at Pfizer Pharma GmbH as a biometrician. In this capacity he planned and analysed clinical studies. In 1995, he was named head of biometrics. He was in charge of biometric support for clinical trials and NIS studies. Since 2010, he has led the Health Technology Assessment Group at Pfizer Germany, which is responsible for HTA and outcomes research. The team is mainly responsible for the development of AMNOG dossiers and strategies as well as the advisory meetings and hearings at the G-BA. For many years he has been working actively with a subcommittee of the vfa (Die forschenden Pharma-Unternehmen, Germany) and is spokesman of the subcommittee on benefit assessment at the vfa. He is working on the further development of methods in performance assessment in Germany and has already had several publications.

Jolanda Koenders obtained her master’s of science and health technology as­sessment and has contributed to pharmaceutical industry in the clinical de­partments, medical affairs, market access and HEOR. She is currently heading the pricing and market access department within Novartis in the Netherlands, and thereby she’s responsible for access and innovative contracts for diverse therapeutic areas (including neuroscience, ophthalmology and immunology and dermatology). Jolanda is a contributor to the professional organisation of Pharmaceutical Industry Netherlands.

Axel Boehnke is the director of market access for MorphoSys AG, responsible on a global level. He´s fully responsible for all market access aspects, patient access and early evidence planning as well as actions to accelerate access to patients, currently with the focus on DLBCL. His experience in this area of work has allowed him to develop a sophisticated market access skill set. Axel also has in-depth knowledge and expertise in the specialised business, like oncology, autoimmune diseases, (ultra) orphan diseases, hepatology, anti-viral, etc. He also has in-depth experience in therapeutic mass markets like cardiovascular or osteoporosis, with respective payer-interactions and contract­ing. He started with Humira at Abbott in national responsibility, headed to the department of market access and managed care at Servier, and then served for experience in biopharmaceutical industry for the last four years, mainly at Intercept, where he was responsible for market access, pricing and reimburse­ment in the DACH cluster. Before joining the pharmaceutical industry 15 years ago, he worked at one of the biggest German payers. He is a health economist (University of Cologne) by education. In addition, he holds a master’s degree in health and medical management (University Erlangen-Nurnberg). Axel is a member of the German Society of Market Access and the German Society of Health Economics. He heads conferences on market access topics regarding HTA assessment, evidence framing, payer engagement, pricing and reimburse­ment. He published various articles on topics like benefit assessment, market access, healthcare system issues and disease awareness (i.e. in rheumatoid ar­thritis or psoriasis), as well as on claims-data-analysis with real-world evidence.

Massimo is VP at Stratence Partners, a well-known global consulting, systems, and out­sourcing company, and has numerous years of experience helping the organizations worldwide, optimizing Strategies, enhancing Commercial Effectiveness and implement­ing successfully Pricing Excellence. Massimo is a dynamic, pro-active, pragmatic, high performing senior executive, having successfully developed and led organizations and multifunctional teams to achieve outstanding results in international leadership posi­tions. A skilful communicator with highly developed interpersonal skills and ability to engage, influence, develop and motivate both individuals and teams across cultures and functions, shaping the strategy and driving behavioural change in several regions and countries. His professional career highlights include roles as Senior Commercial VP, VP and Portfolio & Supply Chain Director, and Technical Director at leading companies such as PGT Healthcare, Teva Pharmaceuticals, Chiesi Farmaceutici, and Nicim. Massimo has a bachelor’s degree in electronic engineering cum laude from the Università Statale degli Studi (Genova - IT), an Executive MBA from Bocconi SDA (Milan). He fluently speaks Italian, English, and enjoys international Projects to continuously improve his French, Spanish, and Hebrew.

Charles-Etienne de Cidrac started his career in the finance industry, working successively in Derivatives and Asset Management. He joined AXA Investment Managers in 1999 and held various positions in Business Development and Sales in France, Germany, and the UK. 

In 2003, he joined the insurance part of the business and was promoted to Head of International Group Insurance. In 2010, he moved to AXA Corporate Headquarters in the newly formed Global Business Line as Health Director. He oversaw Strategy and Development for the Health Business Line of AXA. His role consisted of defining the Health Insurance Strategy of AXA, monitoring the Health Insurance business, and leading initiatives for development and innovation. He was the promoter of the “Health Payer to Health Partner” transformation strategy of AXA. He is currently working in the Group Risk Management of AXA as Health Director. 

He is a graduate of ESCP Europe and Harvard Business School. He is also an alumnus of the Executive Development Program of the IFHP (International Federation of Health Plans). 

In addition to his role at AXA, Charles-Etienne de Cidrac is a member of the Steering Committee of the World Health Organization Community of Practice on Non Communicable Diseases. He teaches “Health Insurance” at Ecole Supérieur d’Assurances in Paris. 

Last, he holds an Independent Director Position at CFJC (Compagnie Financière Jacques Cœur) as a member of the Company’s Supervisory Board.

Renate Haidinger was born in Berlin in 1958. Concurrent with acquiring her university-entrance diploma she became an interpreter for economics (English- German). She also worked as a freelance journalist since 1977 and specialised in psychology and medicine in 1987. From 1987-89, she was the personal as­sistant of a board member of Xerox USA. From 1996-01, Renate worked on the project ‘Prevention of the abuse of legal and illegal drugs’ that she initiated to protect children and juveniles. In December 2000, she was diagnosed with breast cancer. After she had gone through several surgeries and chemotherapy, she founded a local advocacy group, brustkrebs-muenchen e.V., in December 2001. In 2003 she founded the nationwide organisation Brustkrebs Deutsch­land e.V. (German Breast Cancer Association) together with a group of doctors, breast cancer patients and others. Since 2002, Renate has offered a weekly consultation possibility at the Munich University Clinic, Munich-Großhadern. She was chair of an international patient advocate subcommittee for the in­ternational ‘Abreast Registry’ and is a member of the advisory board of the ‘Success’- clinical trial. She also is part of the “Independent Data Monitoring Committee” of a big German study group (since 2004). She is author and co-author of national and international publications and had posters at congresses in Germany, Europe and the USA. She is a faculty member of the ABC 4 and a member of the panel of ABC 5, member of the global alliance for metastatic breast cancer and the expert working group for the policy road map for meta­static breast cancer. She is also member of several cancer societies: ASCO, Deutsche Krebsgesellschaft, ASORS, DGGG and DGS. In 2012, Renate received the Federal Cross of Merit from the German President, Joachim Gauck.